Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Alexander Morse"'
Autor:
Panagiotis A. Konstantinopoulos, Chiara Battelli, Ursula A. Matulonis, Jennifer Curtis, Jacqueline Watson, Alexander Morse, Dipanjan Chowdhury, Joyce F. Liu, Young Eun Choi
Publikováno v:
Oncotarget
// Young Eun Choi 1 , Chiara Battelli 2 , Jacqueline Watson 1 , Joyce Liu 3 , Jennifer Curtis 3 , Alexander N. Morse 4 , Ursula A. Matulonis 3 , Dipanjan Chowdhury 1 , Panagiotis A. Konstantinopoulos 1, 3 1 Department of Radiation Oncology, Dana Farb
Publikováno v:
Journal of the American College of Cardiology. 73:1137
We evaluated the diameter of the major pedal arteries in patients with risk factors for peripheral arterial disease (PAD). We hoped to identify which patients had arteries (6 French minimum) that would allow us to employ advanced atherectomy devices
Autor:
Elena Levantini, Gerburg M. Wulf, Alexander Morse, Dipanjan Chowdhury, Hai Hu, Chiara Battelli, Youngeun Choi, Panagiotis A. Konstantinopoulos
Publikováno v:
Cancer Research. 73:3054-3054
Patients with hereditary epithelial ovarian cancer (EOC) associated with germline BRCA1/2 mutations exhibit improved outcome and high sensitivity to platinum and poly (ADP-ribose) polymerase inhibitors (PARPis) due to an underlying defect in DNA repa
Autor:
Elena Levantini, Gerburg M. Wulf, Hai Hu, Alexander Morse, Chiara Battelli, Panagiotis A. Konstantinopoulos
Publikováno v:
Cancer Research. 73:3339-3339
Double-strand DNA break (DSB)-inducing agents such as platinum analogues and poly (ADP-ribose) polymerase inhibitors (PARPis) exhibit significant antitumor activity in epithelial ovarian cancer (EOC). Approximately 50% of patients with EOC harbor gen
Autor:
Serguei N. Lvov, Rich Schatz, Soohyun Kim, Sanchit Khurana, Alexander Morse, Mike Chung, Mark Fedkin
Publikováno v:
ECS Meeting Abstracts. :1816-1816
not Available.
Autor:
Nishan Tchekmedyian, Alexander Morse, Stephen A. Cannistra, Panagiotis A. Konstantinopoulos, Sanisetty Srisowmya
Publikováno v:
Cancer Research. 72:2981-2981
A subset of sporadic epithelial ovarian cancer (EOCs) may harbor a “BRCAness” phenotype characterized by improved outcome and enhanced responsiveness to platinum analogues and PARP inhibitors, similar to their BRCA1/2 mutated counterparts. This B